Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-1182
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease ; volume:59 ; number:4 ; day:20 ; month:1 ; year:2022 ; pages:2171-2189 ; date:4.2022
Molecular neurobiology ; 59, Heft 4 (20.1.2022), 2171-2189, 4.2022
- Urheber
-
Tardiff, Daniel F.
Lucas, Matthew
Wrona, Iwona
Chang, Belle
Chung, Chee Yeun
Bourdonnec, Bertrand Le
Rhodes, Kenneth J.
Scannevin, Robert H.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12035-021-02695-1
- URN
-
urn:nbn:de:101:1-2022070207275291959371
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tardiff, Daniel F.
- Lucas, Matthew
- Wrona, Iwona
- Chang, Belle
- Chung, Chee Yeun
- Bourdonnec, Bertrand Le
- Rhodes, Kenneth J.
- Scannevin, Robert H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
Clinical Criteria for the Diagnosis of Parkinson’s Disease
Genetic testing for Parkinson’s disease in clinical practice
Clinical pharmacology
Landscape of pain in Parkinson’s disease : impact of gender and Parkinson’s disease clinical phenotype
The clinical diagnosis of Parkinson's disease
Clinical aspects of palliative care in advanced Parkinson’s disease
Constipation and pain in Parkinson’s disease: a clinical analysis
Gut microbiota helps identify clinical subtypes of Parkinson’s disease
Pediatric clinical pharmacology
BMC clinical pharmacology
Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
Clinical Criteria for the Diagnosis of Parkinson’s Disease
Genetic testing for Parkinson’s disease in clinical practice
Clinical pharmacology
Landscape of pain in Parkinson’s disease : impact of gender and Parkinson’s disease clinical phenotype
The clinical diagnosis of Parkinson's disease
Clinical aspects of palliative care in advanced Parkinson’s disease
Constipation and pain in Parkinson’s disease: a clinical analysis
Gut microbiota helps identify clinical subtypes of Parkinson’s disease
Pediatric clinical pharmacology
BMC clinical pharmacology
Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
Clinical Criteria for the Diagnosis of Parkinson’s Disease
Genetic testing for Parkinson’s disease in clinical practice
Clinical pharmacology
Landscape of pain in Parkinson’s disease : impact of gender and Parkinson’s disease clinical phenotype
The clinical diagnosis of Parkinson's disease
Clinical aspects of palliative care in advanced Parkinson’s disease
Constipation and pain in Parkinson’s disease: a clinical analysis
Gut microbiota helps identify clinical subtypes of Parkinson’s disease
Pediatric clinical pharmacology